Compare BIO & MTZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BIO | MTZ |
|---|---|---|
| Founded | 1952 | 1929 |
| Country | United States | United States |
| Employees | 7450 | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Water Sewer Pipeline Comm & Power Line Construction |
| Sector | Industrials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 22.9B |
| IPO Year | N/A | 2005 |
| Metric | BIO | MTZ |
|---|---|---|
| Price | $262.97 | $298.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 19 |
| Target Price | ★ $358.50 | $285.78 |
| AVG Volume (30 Days) | 235.7K | ★ 910.3K |
| Earning Date | 04-30-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 146.12 |
| EPS | N/A | ★ 5.07 |
| Revenue | N/A | ★ $14,299,171,000.00 |
| Revenue This Year | $2.74 | $14.40 |
| Revenue Next Year | $3.05 | $9.38 |
| P/E Ratio | ★ $9.72 | $61.66 |
| Revenue Growth | N/A | ★ 16.22 |
| 52 Week Low | $211.43 | $99.70 |
| 52 Week High | $343.12 | $315.00 |
| Indicator | BIO | MTZ |
|---|---|---|
| Relative Strength Index (RSI) | 40.24 | 56.86 |
| Support Level | $239.33 | $164.00 |
| Resistance Level | $289.61 | $310.36 |
| Average True Range (ATR) | 7.46 | 13.16 |
| MACD | 0.44 | -1.03 |
| Stochastic Oscillator | 19.99 | 53.28 |
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
MasTec is a leading infrastructure construction company operating mainly in North America across a range of industries. Its primary activities include engineering, building, installing, maintaining, and upgrading communications, oil and gas, utility, renewable energy, and other infrastructure. MasTec reports its results under five segments: communications; clean energy and infrastructure; pipeline infrastructure; power delivery; and other.